IgG Fc-Binding Peptide-Conjugated Pan-CoV Fusion Inhibitor Exhibits Extended In Vivo Half-Life and Synergistic Antiviral Effect When Combined with Neutralizing Antibodies

The peptide-based pan-coronavirus fusion inhibitor EK1 is in phase III clinical trials, and it has, thus far, shown good clinical application prospects against SARS-CoV-2 and its variants. To further improve its in vivo long-acting property, we herein developed an Fc-binding strategy by conjugating...

Descripción completa

Detalles Bibliográficos
Autores principales: Su, Xiaojie, Huang, Ziqi, Xu, Wei, Wang, Qian, Xing, Lixiao, Lu, Lu, Jiang, Shibo, Xia, Shuai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10526447/
https://www.ncbi.nlm.nih.gov/pubmed/37759683
http://dx.doi.org/10.3390/biom13091283

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10526447/
https://www.ncbi.nlm.nih.gov/pubmed/37759683
http://dx.doi.org/10.3390/biom13091283

Ejemplares similares